CANNRA Responds to FDA Announcement

Their Statement

Today, the U.S. Food and Drug Administration (FDA) released a statement on cannabidiol (CBD) and reported that they would work with Congress to pursue a new regulatory pathway for CBD.

The Cannabis Regulators Association (CANNRA) looks forward to FDA’s work with Congress to develop a regulatory pathway for CBD products. While CBD is largely the focus of today’s announcement, CANNRA feels strongly that clarity is urgently needed on a more comprehensive regulatory pathway that addresses the growing number of cannabinoid products (many of which are intoxicating) that are being chemically and synthetically derived from hemp and CBD, including cannabinoids like Delta-8-THC, Delta-10-THC, HHC, and THC-O-Acetates. These types of products pose a myriad of consumer safety and public health risks and create challenges for state cannabis and hemp regulators because they largely fall outside of any current federal regulation. Consumers see these hemp-derived cannabinoid products at retail and, understandably, presume they are federally regulated, when that is not the case. In addition, consumers may not have sufficient information to know whether they are purchasing naturally derived or synthetically derived products.

CANNRA recently released a series of factsheets providing more information about hemp-derived cannabinoid products, and the urgency of the regulatory challenges they currently pose to consumer safety, public health, youth, and regulated markets.

CANNRA urges Congress and the FDA to follow the lead of a number of CANNRA-member states by proposing and implementing a comprehensive federal regulatory framework for hemp-derived cannabinoid products, and not just for CBD. Furthermore, state cannabis and hemp regulators have a unique perspective on this issue and need to be at the table as federal regulatory frameworks are discussed and implemented.

Primary Sponsor

Karma Koala Podcast

Top Marijuana Blog